trending Market Intelligence /marketintelligence/en/news-insights/trending/batj1fbrqnxmaavlqthjpg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Amphastar gains final victory over Momenta, Sandoz in patent dispute

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Amphastar gains final victory over Momenta, Sandoz in patent dispute

Amphastar Pharmaceuticals, Inc. won a patent dispute brought against the company by Momenta Pharmaceuticals, Inc. and Novartis AG's generics unit, Sandoz International GmbH.

In affirming an earlier verdict by a federal jury, the U.S. District Court for the District of Massachusetts noted that Momenta's U.S. patents covering a method to manufacture a generic version of the medicine Lovenox were invalid and unenforceable.

Momenta and Sandoz filed a lawsuit against Amphastar in 2011 after the U.S. Food and Drug Administration approved Amphastar's generic version of the blood thinner, which is sold as Lovenox by Sanofi.

The court also denied a motion by Momenta and Sandoz to dismiss Amphastar's antitrust lawsuit against the companies. The lawsuit alleges that both companies prevented Amphastar from selling an injectable version of enoxaparin sodium, the main component of Lovenox, and thus excluded a cheaper alternative of the drug from entering the market.

"We are very happy to receive the court's final judgment in Amphastar's favor as well as the court's denial of Momenta's and Sandoz's motion to dismiss our antitrust lawsuit. We can now proceed to file a motion to collect the $100 million bond in the patent case and proceed to assert our treble damages under antitrust law," Amphastar CEO Jack Zhang said in a statement.